SOURCE-BASED EDITORIAL GUIDE · SPECIALIST REVIEW PENDING

What the evidence says

A 2021 randomized trial studied NMN in postmenopausal women with prediabetes and overweight or obesity. It reported improved muscle insulin sensitivity, a specific metabolic outcome.

This is a narrowly defined study population. The result does not establish longer life, a treatment for all adults or the effectiveness of every commercially available NMN product.

THE TAKEAWAY

A metabolic signal deserves study, not extrapolation.

Where the evidence stops

No personal dose or product recommendation follows from this study. Regulatory status requires a separate, jurisdiction-specific check.

Read the original sources

Source pages checked on 23 October 2026. This is not the publication date of each study. Original sources may be in English.

Yoshino et al. · Science, 2021pubmed.ncbi.nlm.nih.gov · Sources checked: 2026-10-23FDA · Dietary supplement questions and answerswww.fda.gov · Sources checked: 2026-10-23European Commission · Novel food cataloguefood.ec.europa.eu · Sources checked: 2026-10-23

Questions worth taking further

  • Was the outcome measured in humans, animals or cells?
  • Does the study population match the people in the claim?
  • What benefits, harms and uncertainties remain unmeasured?